Lynparza Tablets Approved in EU to Treat Advanced, Platinum-sensitive Ovarian Cancers

Lynparza Tablets Approved in EU to Treat Advanced, Platinum-sensitive Ovarian Cancers
The European Medicines Agency (EMA) has approved Lynparza (olaparib) tablets as a maintenance therapy for ovarian cancer patient who have relapsed, but have had a complete or partial response to platinum-based chemotherapy, and regardless of BRCA mutations. The new formulation of Lynparza as tablets — marketed by AstraZeneca and Merck (MSD outside North America) — was approved to treat high-grade epithelial ovarian,

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *